Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal CancerFausto Petrelli, Alberto F. Sobrero, Roberto Labianca et al.|JAMA Oncology|2020Cited by 49
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup AnalysisGerardo Rosati, Maria Di Bartolomeo, Stefano Tamberi et al.|The Oncologist|2020Cited by 11
Gemcitabine/cisplatin in advanced transitional cell carcinoma of the urinary tract (TCC): a phase II multicenter trialS. Mancarella, M. De Lena, Vito Lorusso et al.|European Journal of Cancer|1999Cited by 4
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Cancers|2023Cited by 2
Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysisG. Rosati, Giacomo Bregni, Francesca Galli et al.|Annals of Oncology|2019Cited by 0